HROW

AI Memo

Harrow

As of 2026-09-06/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

TYRVAYA acquisition close • 2026-12-05

Base target: $44 / p=55% prob

Biggest risk

The first-half revenue pace was lighter than expected, VEVYE previously created gross-to-net pressure, and future value depends on execution across pricing, payer access, portfolio integration, and profitability. The stock could re-rate lower if reiterated guidance is not supported by H2 results.

Invalidation

Break below $29 or thesis failure.

What would change my mind?

Harrow has improving commercial indicators: Q2 revenue rose 60% sequentially, VEVYE revenue reached $29.4 million, and IHEEZO and TRIESENCE posted record demand metrics. The bull case requires H2 conversion of demand into net revenue and EBITDA while TYRVAYA expands the portfolio.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-06

Base target

$44

p=55%

Bull target

$52

p=25%

Bear target

$29

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

VEVYE access and IHEEZO pricing conversion
Conversion of H2 demand into 2026 profitability
Harrow has improving commercial indicators: Q2 revenue rose 60% sequentially, VEVYE revenue reached $29.4 million, and IHEEZO and TRIESENCE posted record demand metrics.

BearKey bullets

H2 demand may not convert into reported net revenue and Adjusted EBITDA at the reiterated guidance levels.
IHEEZO pricing improvements and channel normalization may not persist as expected.
Product availability, compounded formulations, clinical programs, and future regulatory approvals carry execution and regulatory risk.

WatchKey bullets

TYRVAYA acquisition close

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $44 (p=55%)

Target spread vs base: +20% / -33%

Scenario probabilities

Bull Target: $52 (p=25%)Base Target: $44 (p=55%)Bear Target: $29 (p=20%)

Commentary

Recent news is concentrated around Q2 results and carries a constructive operating tone, but coverage is low. Social sentiment, options skew, short interest, employee sentiment, and post-print analyst revisions are unavailable in the packet; the positive view therefore remains tentative and monitoring-oriented.

As of 2026-09-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

VEVYE access and IHEEZO pricing conversion
Conversion of H2 demand into 2026 profitability

Scenarios

Bull Target (Scenario probability)

$52 / p=25% prob

Base Target (Scenario probability)

$44 / p=55% prob

Bear Target (Scenario probability)

$29 / p=20% prob

Analysis 2026-09-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-05
TYRVAYA acquisition close
Harrow announced the acquisition of TYRVAYA, expected to close during the second half of 2026. A successful close could broaden the ophthalmic portfolio, but the value depends on integration, payer access, and commercial execution [#SEC-8K-2026-08-10].
Prob 65.00% • Move 10.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

VEVYE access and IHEEZO pricing conversion
2026-12-05
Expanded VEVYE formulary coverage became effective August 1, while IHEEZO pricing improved approximately 25% effective July 1. The key near-term question is whether these changes convert demand into sustained net revenue and profitability during H2 2026 [#SEC-8K-2026-08-10] [#PR-EARNINGS-2026-08-17].
Prob 70% • Move 8% • Priced-in 55%

Long-term Catalysts

Months to a year

Conversion of H2 demand into 2026 profitability
2026-12-31
Harrow reiterated 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA guidance of $80 million to $100 million. Sustained VEVYE growth, IHEEZO pricing improvement, and TRIESENCE demand would support the thesis, while failure to convert demand would weaken it [#SEC-8K-2026-08-10].
Prob 60% • Move 15% • Priced-in 45%

Risks

H2 demand may not convert into reported net revenue and Adjusted EBITDA at the reiterated guidance levels.
IHEEZO pricing improvements and channel normalization may not persist as expected.
Product availability, compounded formulations, clinical programs, and future regulatory approvals carry execution and regulatory risk.
TYRVAYA closing, integration, payer access, and commercial execution could disappoint.
VEVYE gross-to-net economics and payer coverage assumptions could again create revenue pressure.

Peers

Symbol	Summary
AZTA	Similar market capitalization and broad sector classification, but not a direct ophthalmic commercial peer; valuation read-through is limited.
MRVI	Similar market capitalization and life-sciences exposure, but its business model differs materially from Harrow's ophthalmic product portfolio.
AMGN	Much larger and more diversified biopharma company; useful as a scale and therapeutic-sector benchmark, not a close operating comp.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-06

Loading AI feed…

Symbol

Summary

AZTA

Similar market capitalization and broad sector classification, but not a direct ophthalmic commercial peer; valuation read-through is limited.

MRVI

Similar market capitalization and life-sciences exposure, but its business model differs materially from Harrow's ophthalmic product portfolio.

AMGN

Much larger and more diversified biopharma company; useful as a scale and therapeutic-sector benchmark, not a close operating comp.